Physician

Maura Kelly Hagan, M.D.

According to 2025 Medicare claims, Maura Hagan, M.D. (NPI: 1699738260) practices hematology/oncology in the Richmond, VA market, with the plurality of this provider's patient population coming from Hanover, VA. This provider's primary affiliated billing organization is VIRGINIA CANCER INSTITUTE INCORPORATED (NPI: 1730130980; TIN: 54-1066435) and primary practice location at 23116-3834.

Hagan's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 878 traditional Medicare patients, billed 131,430 HCPCS/CPT codes, and received $2,864,046 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,257 prescription claims across 355 beneficiaries totaling $6,506,193 in drug costs, led by Brukinsa (Zanubrutinib). DME data shows 113 claims. Open Payments data shows 74 records totaling $1,827. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $2,476,495 to $6,506,193. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $11,046 to $2,273.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,104	165,557	$2,125,555
2016	1,112	219,579	$3,349,334
2017	1,071	277,520	$3,886,402
2018	1,093	311,920	$3,739,943
2019	1,090	266,015	$3,287,841
2020	1,061	220,487	$3,762,851
2021	1,080	252,595	$4,504,805
2022	983	201,973	$3,309,286
2023	965	231,233	$3,437,441
2024	878	131,430	$2,864,046

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	330	2,153	$2,476,495
2016	331	2,230	$2,932,974
2017	350	2,215	$3,368,607
2018	370	2,425	$3,871,814
2019	337	2,178	$4,223,956
2020	356	2,303	$4,472,679
2021	352	2,196	$4,636,765
2022	364	2,197	$4,066,219
2023	332	2,059	$5,044,383
2024	355	2,257	$6,506,193

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	87	418	$104,769
2016	33	318	$58,359
2017	88	243	$56,923
2018	106	260	$37,984
2019	77	178	$21,898
2020	95	244	$23,446
2021	80	223	$19,893
2022	59	161	$12,673
2023	49	169	$34,881
2024	30	113	$8,871

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	250	460	$92
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	536	769	$59
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	122	191	$44
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	346	416	$12
96372	Injection of drug or substance under skin or into muscle	169	617	$10

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Brukinsa	Zanubrutinib	63	1,890	$905,903
Imbruvica	Ibrutinib	44	1,232	$677,470
Revlimid	Lenalidomide	32	868	$622,481
Lenalidomide	Lenalidomide	44	1,176	$581,267
Pomalyst	Pomalidomide	23	644	$528,389

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8030	Breast prosthesis, silicone or equal, without integral adhesive	N	11	11	$3,749
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	19	21	$2,749
J8521	Capecitabine, oral, 500 mg	N	N/R	38	$1,651
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	29	$546
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	14	$176

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	74	$1,827	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Maura Kelly Hagan, M.D.?

Tedicare shows public-source Medicare data for Maura Kelly Hagan, M.D. (NPI 1699738260), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Maura Kelly Hagan, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Maura Kelly Hagan, M.D.?

Maura Kelly Hagan, M.D. is linked to VIRGINIA CANCER INSTITUTE INCORPORATED (billing NPI 1730130980) in the available physician profile data.

Does Maura Kelly Hagan, M.D. have Open Payments data?

Maura Kelly Hagan, M.D. has 74 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.